Sunesis Poised for Phase 3 Trial of Voreloxin in Acute Myeloid Leukemia After Completing Formal End-of-Phase 2 Meetings With FDA
Company on Track to Initiate Pivotal Study in Second Half of 2010
CNNMoney.com
Source: Marketwire
February 25, 2010: 07:30 AM ET
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) related to its lead compound,...
Combination Therapy With Midostaurin Improves Survival of Acute Myeloid Leukemia Patients With FLT3 Mutations, Phase 1
ScienceDaily (Dec. 7, 2009) — A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Dec. 7....
UPDATE 1-Sunesis cancer drug gets orphan status, shares soar
Thu Nov 5, 2009 9:45am EST
* FDA grants orphan drug status to Voreloxin * Shares up as much as 28 pct
Nov 5 (Reuters) - Biopharmaceutical company Sunesis Pharmaceuticals (SNSS.O) said its experimental cancer drug, voreloxin, got an orphan drug designation from U.S. health regulators, sending its shares soaring 28 percent.
Remission rates for primary central nervous system lymphoma have been boosted by adding cytarabine to high-does methotrexate monochemotherapy, according to research published in the Lancet.
A team at the San Raffaele H Scientific Institute in Milan reports that the combination resulted in remission rates of 46% compared with 18% for methotrexate alone. Partial response rates were 69% and 40%.
Intense Chemotherapy Wards Off Recurrence in Half of Mantle Cell Lymphoma Patients After Seven Years
Tue 09-Dec-2008, 11:40 ET
Newswise — More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.
